



PPD Enhances its Portfolio of EDC Services with Oracle® Remote Data Capture Onsite 4.5.3

WILMINGTON, N.C. (April 22, 2008) - PPD, Inc. (Nasdaq: PPDI) today announced that it has integrated Oracle's newest electronic data capture (EDC) solution into its suite of clinical trial management applications providing clients and investigators easier, faster navigation to collect and report real-time data for large-scale, global clinical trials.

Oracle® Remote Data Capture Onsite 4.5.3, the latest version of Oracle Remote Data Capture (RDC), is one of two full-service EDC technologies that PPD offers clients. PPD GlobalView, the company's proprietary EDC technology, is available for global registries and post-approval studies. In addition, PPD offers clients experience with more than 60 third-party EDC vendor studies, depending upon customer preferences and needs.

"Ease of use is critical when incorporating EDC technology into clinical trials," said Susan Atkinson, senior vice president, biostatistics and data management. "Designed for use by investigators and clinical research associates, Oracle Remote Data Capture Onsite 4.5.3 offers a simple interface with cleaner, quicker data entry, enabling our clients to complete clinical trials faster and accelerate time to market of new therapies.

"As a customer adviser, we worked closely with Oracle to improve RDC, specifically to increase investigator site performance, simplify the user interface, eliminate software installation and provide a fully Web-based EDC system."

An entirely Web-based system, RDC Onsite 4.5.3 requires no software download or installation. With a zero footprint, HTML data entry window, the application can be accessed globally with only an Internet connection and includes a 128-bit encryption to ensure data security.

This version features case report forms that are easy-to-navigate, search and sort and a robust system of edit checks to ensure data accuracy. Furthermore, PPD has integrated its interactive voice response system with the RDC platform. Investigators can now enroll and/or randomize patients while transmitting enrollment data into the Oracle Clinical RDC system, all during the same phone call.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 31 countries and more than 10,400 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at <http://www.ppd.com>.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the performance and value of this technology, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: rapid technological advances that make our products and services less competitive; risks associated with and dependence on collaborative relationships; competition within the outsourcing industry; continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; the ability to attract and retain key personnel; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+919 456 5890

sueann.pentecost@rtp.ppd.com

Analysts/Investors:

Craig Eastwood

+910 558 7585

craig.eastwood@wilm.ppd.com